Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst /Institutional Investor Meeting.09-11-2021
09-11-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Clarification / Confirmation On News Item
As per letter attached09-11-2021
Sun Pharmaceutical Industries Ltd - 524715 - Clarification sought from Sun Pharmaceutical Industries Ltd
The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd with respect to news article appearing on https://economictimes.indiatimes.com/ November 07, 2021 titled "Sun pharma, Lupin recall products in US market".The reply is awaited.08-11-2021
Sun Pharma, Lupin recall products in US market, says USFDA
As per the latest enforcement report by the US Food and Drug Administration (USFDA), Sun Pharma is recalling 22,752 blister packs of Loratadine-D extended-release tablets, used for the treatment of allergic rhinitis and the common cold, in the US market.07-11-2021
Sun Pharma's two US arms to pay $85 million
The subsidiaries will make an aggregate payment amounting to a combined total of $85 million in exchange for a full release of all claims asserted against them in the direct purchaser action by the settlement class members.06-11-2021
Sun Pharmaceutical Industries Ltd - 524715 - Disclosure Under Regulation 30 Read With Schedule III Of SEBI (Listing Obligation And Disclosures Requirements) Regulations, 2015, As Amended ('Listing Regulations') -Signing Of Settlement Agreements With The Direct Purchaser Plaintiffs In The In Re Generic Pharmaceuticals Pricing Antitrust Litigation In The Eastern District Of Pennsylvania (USA) By Our 2 Subsidiary Companies.
Please find enclosed intimation under the subject matter.05-11-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosure Under Regulation 30 Read With Schedule III Of SEBI (Listing Obligation And Disclosures Requirements) Regulations, 2015, As Amended ('Listing Regulations') -Signing Of Settlement Agreements With The Direct Purchaser Plaintiffs In The In Re Generic Pharmaceuticals Pricing Antitrust Litigation In The Eastern District Of Pennsylvania (USA) By Our 2 Subsidiary Companies.
Please find enclosed intimation under the subject matter.05-11-2021
Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.05-11-2021
Most analysts raise target prices on Sun Pharma after strong Q2
CLSA, which raised the target price on Sun Pharma the most, said the drug maker's results were above estimates with key geographies performing well. Sun Pharma shares ended down 3.3% at 788 on Wednesday.04-11-2021
Sun Pharma's margin improvements drive earnings beat
Structural factors such as improved gross margin due to speciality sales, reduced costs related to development of speciality products will keep Sun Pharma's margins elevated compared to the past03-11-2021